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Abstract
Context and objective
Prader-Willi syndrome (PWS) is characterized by early-onset hyperphagia and increased
circulating levels of the orexigenic Acylated Ghrelin (AG) hormone with a relative deficit of
Unacylated Ghrelin (UAG). AZP-531, a first-in-class UAG analog, was shown to inhibit the
orexigenic effect of AG in animals, to improve glycemic control and decrease body weight in
humans. We aimed to investigate the safety and efficacy of AZP-531 in patients with PWS
for whom no approved treatment for hyperphagia is currently available.
Methods and design
Multi-center, randomized, double-blind, placebo-controlled trial. Forty-seven patients with
genetically confirmed PWS and evidence of hyperphagia received daily subcutaneous injec-
tions of AZP-531 (3 and 4 mg for 50–70 kg and >70 kg body weight, respectively) or match-
ing placebo for 14 days. Assessments included adverse events, vital signs, safety
laboratory tests, the Hyperphagia Questionnaire (HQ), patient-reported appetite, body com-
position and glycemic measures.
Results
AZP-531 was well tolerated. There was a significant improvement with AZP-531 versus pla-
cebo in the mean total score, the 9-item score and the severity domain score of the HQ (p <
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.05). The highest reduction in the total and 9-item scores was observed in AZP-531 subjects
with the highest hyperphagia score at baseline. Findings were supported by a reduction in
appetite scores observed with AZP-531 only. Body weight did not change in both groups
while a significant reduction in waist circumference and fat mass was observed only with
AZP-531. AZP-531 significantly decreased post-prandial glucose levels in a baseline glu-
cose dependent fashion.
Conclusions
AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic
issues in patients with PWS. These findings support further investigation in longer-term clini-
cal trials.
Introduction
Prader-Willi Syndrome is a rare genetic disorder that results from lack of expression of pater-
nally inherited imprinted genes in chromosomal region 15q11.2-q13 caused either by paternal
deletion (65–75%), maternal uniparental disomy (20–30%) or imprinting defects [1]. Hyper-
phagia is the central and constant feature of the syndrome starting after the first 3 years of life
and is associated with abnormal and extreme behaviors toward food [2, 3]. Hyperphagia and
food-related behaviors dramatically impair socialization and occupational performance and
substantially deteriorate quality of life of patients and caregivers [4, 5] and is responsible for
significant morbidity and mortality [6]. There is no approved pharmacological treatment for
hyperphagia.
Ghrelin is a 28-amino-acid gut-derived hormone that circulates in 2 forms: 1) Acylated
ghrelin (AG) that binds the Growth Hormone Secretagogue Receptor (GHSR) and has orexi-
genic, obesogenic and diabetogenic properties [7–9] and 2) Unacylated ghrelin (UAG) that
acts through GHSR independent pathways and was shown to inhibit these effects [10–13].
Both molecules share protective effects from oxidative stress and inflammation on various cell
types including ß-cells, cardiomyocytes, skeletal muscle cells and endothelial progenitor cells
that have been shown in vitro and in vivo [14–18]. Many reports have documented that fasting
and post-prandial circulating levels of total ghrelin are elevated in PWS at all ages, as compared
to lean and obese subjects [19–24]. A large recent study that included 138 children and adults
with PWS has shown that this is due to high levels of AG and relatively low levels of UAG that
are observed when hyperphagia and obesity develop [25]. In PWS, ghrelin levels have been
shown to positively correlate to ratings of hunger [22] and because of the role of AG in stimu-
lating appetite, elevated AG levels in PWS are hypothesized to contribute to hyperphagia.
Antagonizing or blocking the effects of AG on food intake, body weight and glucose metab-
olism has emerged in the past decade as an attractive pharmaco-therapeutic target. Antago-
nists and inverse agonists of the AG receptor GHSR, as well as AG-blocking agents have been
designed to this end, but mixed results have been obtained so far in animal models while clini-
cal efficacy data are lacking ([26, 27]). On the other hand, inhibitors of the Ghrelin O-Acyl-
transferase (GOAT) enzyme responsible for acylation are still at an early stage of investigation
and no efficacy data is available [27]. UAG is not an antagonist of GHSR and acts as a func-
tional inhibitor of AG, which has appeared as a valuable approach particularly as it may benefit
clinical conditions associated with elevated circulating AG levels and a relative deficit in
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circulating UAG levels such as PWS. As opposed to approaches targeting GHSR or AG, this
approach may in addition preserve protective effects from oxidative stress and inflammation
on tissues, which is of particular relevance in metabolic disorders.
AZP-531 is a cyclic 8 amino-acid analog of UAG with improved plasma stability and phar-
macokinetics [28] and reproduces the pharmacological effects of UAG [11, 29]. In humans,
AZP-531 has a mean half-life of 3 hours and is suitable for once-daily dosing and has been
shown to improve glucose control and decrease weight in Phase 1 clinical trials [30]. As a first
investigation in patients with PWS, the present study has been designed as a 2-week proof-of-
concept study to assess the safety and efficacy of AZP-531 administration in improving food-
related behaviors. Additional assessments included body composition and glycemic measures.
Materials and methods
Trial design and overview
This study was a randomized, double-blind, placebo-controlled trial conducted between Janu-
ary 19, 2015 and January 7, 2016 at 7 clinical research and university-affiliated sites with strong
medical expertise in PWS located in France, Spain, and Italy (EudraCT: 2014-001670-34).
The protocol for this trial and supporting CONSORT checklist are available as supporting
information; see S1 CONSORT Checklist and S1 Study Protocol.
The trial was conducted in strict accordance with the principles expressed in the Declara-
tion of Helsinki and Good Clinical Practice The study protocol was approved by the respective
national Regulatory Bodies and by the following ethics committees:
• For Spain: Comite´ E´tico de Investigacio´n Clı´nica de la Corporacio´ Sanitària Parc Taulı´ de
Sabadell (Favorable opinion received on November 04th 2014).
• For France: Comite´ de Protection des Personnes Sud-Ouest et Outre-Mer II (Favorable
opinion received on November 07th 2014);
• For Italy: Comitato Etico dell’Ospedale Pediatrico Bambino Gesu` (Favorable opinion
received on July 17th 2015)
Eligible patients were randomly assigned in a ratio of 1:1 to receive daily subcutaneous (sc)
injections of either AZP-531 (3 and 4 mg for 50–70 kg and >70 kg body weight, respectively)
or matching placebo, 30 minutes prior to breakfast for 14 days. Dose selection was based on
data from previous clinical studies in obese subjects and patients with Type 2 diabetes showing
that daily administration of AZP-531 at doses of 30 μg/kg and 60 μg/kg for 2 weeks were well
tolerated and were associated with pharmacodynamic effects [30]. The study drugs were pro-
vided as lyophilized powder for reconstitution in 0.9% sodium chloride for injection and were
of identical appearance. Randomization was stratified based on genetic subtype (deletion,
non-deletion) and was performed using an Interactive Web Response System according to a
computer-generated randomization schedule prepared by an independent statistician.
Patients, investigators, study teams and the sponsor Alize´ Pharma were unaware of the group
assignments. Patients were admitted to the study center for study assessments performed on
Day -1 (baseline), on Day 1 (first dose) and Day 14 (last dose). Patients were discharged from
hospital following study assessments and were resident at home during the study period
(named here home-residents). At Hendaye site,France, a PWS-dedicated unit that provides
personalized management strategy including weight control, patients were resident at the hos-
pital during the whole study period.
Data were collected at each site and statistical analyses were performed by ICTA PM
(Dijon, France) and Excelsus Statistics (Montre´al, Canada).
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Participants
Eligible participants were male and female subjects with genetically confirmed PWS estab-
lished by standard DNA methylation test or fluorescent in situ hybridization, and evidence of
hyperphagia as judged by the investigator. Severity of hyperphagia was scored at baseline
(week 0) using a 7-point severity scale. Individuals aged 18 to 40 years inclusive were recruited
at first-stage. The upper age limit was subsequently raised to 50 years in order to have a study
population as representative as possible of the general adult PWS population. Following review
by an independent Data Monitoring Committee of safety data for the first 20 adult patients,
inclusion of subjects aged 12 to 17 years was allowed. Growth hormone treatment was permit-
ted if doses had been stable for at least 1 month prior to screening. Key exclusion criteria were
history of chronic liver disease, history of acute or chronic pancreatitis, type 1 diabetes, use of
insulin, use of GLP-1 analogs, use of weight loss agents or drugs known to affect appetite
within 2 months prior screening, and co-morbid condition or disease including respiratory
disease or psychiatric disorder diagnosed less than 1 month prior to screening. Written con-
sent was obtained from patients, parents or legal guardians, as appropriate.
Assessments
Adverse events (AEs) were collected from the signature of the informed consent until the fol-
low-up visit performed on Day 28. In accordance with Good Clinical Practice guidelines and
applicable local regulatory requirements, AEs were recorded on a standardized Adverse Event
form that was included in the patient’s electronic case report form, and described in detail.
Physical exam, measurement of vital signs and laboratory tests including hematology, bio-
chemistry, coagulation, and urinalysis were carried out within 7 days prior to Day 1 (first dos-
ing day) and on Day 14. Laboratory tests were performed at local site laboratories. Follow-up
on AEs was performed on Day 28. Body weight (BW) and waist circumference (WC) were
obtained from patients on Day-1 and Day 14. WC was measured using a standard anthropom-
etry procedure [31]. Fat mass was added to the study assessments subsequent to the trial com-
mencement but before finalization of the statistical plan to further evaluate changes in body
composition. Fat mass data is therefore only available for a subset of patients. Assessment was
performed on Day-1 and Day 14 using bio-impedance (TANITA BC-418MA, Japan, or
OMRON BF-310, OMRON Healthcare Co. Ltd., Japan).
Food-related behaviors were assessed using the Hyperphagia Questionnaire (HQ), a multi-
item disease-specific instrument widely used in clinical practice that has been specifically
designed, developed and validated to capture food-related behaviors in PWS as reported by
care providers [32]. Psychometric properties of the HQ have been explored in the context of
this study and data showed that the instrument was valid and reliable. The questionnaire was
filled in on Day-1 (baseline) and Day 14. Items were rated on a 5-point scale (1 = not a prob-
lem to 5 = severe and/or frequent problem). The following scores were calculated by summing
the following items: a) total score (items 1 to 11), b) behavior domain (items 2, 4, 5, 8, 10), c)
drive domain (items 1, 3, 6, 9) and d) severity domain (items 7, 11) scores. At the time of the
conception and design of the study, there was no established efficacy endpoint for interven-
tional clinical trials in hyperphagia and food-related behaviors associated with PWS. A 9-item
score (items 1, 2, 4–9, 11) has been subsequently added and is presented here Consistent with
discussion the study sponsor and other sponsors had with the US Food and Drug Administra-
tion, item 3 (effort required to redirect) and item 10 (cleverness in obtaining food) have been
removed because they do not comply with FDA guidance on clinical outcome measures that
support pharmaceutical drug development (limit concepts to behaviors observable by care-
giver) [33, 34]. The HQ is provided as supplementary information (see S1 Study Protocol).
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Feelings of appetite were captured using a Patient-Reported Outcome (PRO) instrument
designed for capabilities of patients with PWS and that has been shown to be valid and reliable,
as documented by psychometric evaluations including qualitative interviews. Patients were
asked to indicate how much food they could eat by choosing from among six responses labeled
from “nothing at all” to “a very very large quantity”. Responses were associated with cartoons
representing increasing amounts of food items. Patients were trained and acclimated to the
PRO instrument prior to randomization and were tested on Day-1, Day 1 and Day 14 prior
and after a standardized isocaloric meal (mean number of calories: 313, mean composition for
carbohydrates: 61%, lipids: 22%, and proteins: 17%). Appetite scales were administered imme-
diately following meal and 2 hours following meal. Patients’ responses were scored from 0 to 5
before analysis.
Blood samples for measurements of glucose, insulin, AG and UAG were collected at 30 min
and 180 min post-start of breakfast on Day -1, Day 1 and Day 14 after an overnight fast. Plasma
glucose and serum insulin were determined on Cobas1 analyzers (Roche Diagnostics) at
Biomnis Laboratories (France) by a colorimetric enzymatic method and electrochemilumines-
cence immunoassay (ECLIA), respectively. AG and UAG levels were determined on esterase
inhibitor-treated plasma samples (with AEBSF) using two-step double-antibody sandwich
enzyme immunoassays, obtained from SPIBio (Bertin Pharma, France; A05306 and A05319,
resp.). The limit of detection for AG and UAG is 4 and 6 pg/mL, respectively. Intra-assay and
inter-assay variations are lower than 15% for the two assays.
Statistical analyses
A number of 20 patients per group was considered appropriate for initial evaluation of safety
and efficacy on eating behaviors of AZP-531 in this rare patient population. Statistical analyses
were performed on the full analysis set that included all randomized patients who received at
least one dose of study drug. Adverse events, safety laboratory tests and vital signs were pre-
sented descriptively. For other variables, comparisons of treatment versus placebo at Day 14
were performed using ANCOVA models with baseline Day-1 as covariate. The models
included appropriate factors such as treatment and genetic subtype in addition to the covari-
ate. For HQ, analyses excluded one outlier patient (i.e. studentized residual outside the -3 to 3
range) and supportive non-parametric Mann-Withney tests were performed. Effect size and
95% confidence intervals (CI) were also derived from the ANCOVA using the ESTIMATE
statement in SAS1. Between-days comparisons were performed using repeated analysis mod-
els (based on the MIXED SAS1 procedure with a REPEATED statement) that included appro-
priate factors such as day, treatment, and genetic subtype. An appropriate variance-covariance
matrix was chosen (based on the corrected Akaike information criterion (AICC)) to model the
dependent variable through time within one subject. All tests were two-sided (at α = 0.05).
Because of the environment difference between Hendaye and other sites, prespecified analyses
were performed on HQ in both all patients and in patients that were home-residents (i.e.
excluding Hendaye patients). Repeated ANOVA on the change from baseline for glucose and
insulin were performed on the full set (including effects size and 95% CI from the ESTIMATE
statement in SAS1) and patients identified as having impaired glucose tolerance (IGT) or type
2 diabetes (T2D). Pearson’s coefficient of correlations were calculated to determine the rela-
tionship of the changes from baseline to Day 14 in the HQ scores (total and 9-item) and in the
glucose. Cumulative distribution function (CDF) of patients with a change in the total HQ cal-
culated score from baseline to Day 14 was examined to further characterize the treatment
effect. As distribution of the HQ data suggested a floor effect, the change in the HQ 9-item
scores was also presented descriptively in home-residents that displayed a baseline HQ 9-item
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score19 which was considered acceptable to demonstrate a meaningful treatment effect. Sta-
tistical analyses were performed using SAS1 software version 9.2 or higher.
Results
Patients
Of 48 patients who were screened, 47 patients underwent randomization (one patient did not
meet eligibility criteria) of whom 23 were assigned to receive AZP-531 and 24 to receive pla-
cebo (Fig 1). In AZP-531 and placebo groups, there were 19 and 20 home-resident patients,
respectively. All randomized patients completed the treatment and follow-up periods. Three
adolescents, aged 13, 17 and 17 years, participated in the study and were all in the AZP-531
Fig 1. Enrollment and outcomes.
https://doi.org/10.1371/journal.pone.0190849.g001
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group. Baseline characteristics were comparable between groups with the exception of the
male to female ratio that was higher in the AZP-531 group, although males and females were
equally represented in the study (Table 1). Genetic subtype, Intelligence Quotient, and AG/
UAG ratio data were consistent with published data [25, 35, 36]. All patients were hyperphagic,
Table 1. Baseline characteristics.
Characteristic AZP-531
N = 23
Placebo
N = 24
All
N = 47
Age (y) 28.0 ± 7.7 25.7 ± 5.6 26.8 ± 6.7
Median (min-max) 26.6 (13–46) 24.4 (19–38) 25.5 (13–46)
Age group
<18 years, n 3 0 3
 18 years, n 20 24 44
Male:Female ratio, % 65:35 33:67 49:51
Deletion:non deletiona, % 74:26 67:33 70:30
IQb 61.4 ± 12.0 69.8 ± 21.0 65.6 ± 17.3
Median (min-max) 61.0 (45–87) 65.0 (47–127) 62.0 (45–127)
Weight, kg 87.7 ± 23.6 99.7 ± 26.4 93.8 ±25.5
Median (min-max) 87 (53–138) 91 (65–161) 88 (53–161)
BMI (kg/m2)
All patients 35.1 ± 11.8 40.8 ± 11.8 38.0 ± 12.0
Median (min-max) 32.4 (20.6–64.6) 38.4 (27.1–67.4) 34.0 (20.6–67.4)
 18 years 37.1 ± 11.4 40.8 ± 11.8 39.1 ± 11.6
Median (min-max) 33.7 (24.2–64.6) 38.4 (27.1–67.4) 34.2 (24.2–67.4)
WC (cm) 106.6 ± 17.2 115.2 ± 18.5 111.0 ± 18.2
Median (min-max) 106 (80–139) 111 (92–154) 107 (80–154)
Hyperphagia severity score (/7) 4.52 ± 0.99 4.46 ± 1.38 4.49 ± 1.20
HQ total score (/55)c 30.1 ± 9.2 28.5 ± 7.8 29.3 ± 8.5
HQ 9-item score (/45) 23.1 ± 7.7 21.2 ± 6.6 22.1 ± 7.2
Current use of GH, n 7 4 11
Current use of sex hormones, n 9 10 19
Fasting glucose (mmol/L) 5.15 ± 0.54 5.09 ± 0.67 5.12 ± 0.60
Median (min-max) 5.08 (4.3–6.3) 4.97 (4.3–7.7) 4.98 (4.3–7.7)
Fasting insulind (pmol/L) 77.56 ± 56.18 83.45 ± 42.33 80.58 ± 49.08
Median (min-max) 56.32 (24.4–242.5) 68.88 (38.0–181.5) 62.42 (24.4–242.5)
IGT and T2D, n 5 5 10
Fasting AGe (pg/mL) 84.81 ± 37.27 119.22 ± 86.96 102.01 ± 68.37
Fasting UAGf (pg/mL) 106.87 ± 46.42 158.06 ± 100.28 132.46 ± 81.48
Fasting AG:UAG ratiod 0.77 ± 0.24 0.76 ± 0.33 0.77 ± 0.29
Min-max, minimum-maximum; BMI, body mass index; HQ, hyperphagia questionnaire; GH, growth hormone; IGT, impaired glucose tolerance; IQ, intelligence
quotient (specific test not performed in the context of this study, scores were collected only if available in the subjects’ medical history); T2D, Type 2 diabetes; WC, waist
circumference. Data are expressed as mean ± Standard Deviation (SD) or number, unless stated otherwise.
aThe non-deletion genetic subtype includes uniparental maternal disomy and imprinting defects (when DNA methylation was used for genetic diagnosis additional
testing was performed to distinguish deletion from non-deletion subtypes).
bIntelligence quotient was obtained from 14 patients in each group.
cHQ total score was obtained from 23 patients in each group.
dFasting insulin was obtained from 22 patients in the placebo group.
eAG and AG:UAG ratio were obtained from 22 patients in each group.
fUAG was obtained from 23 patients in each group.
https://doi.org/10.1371/journal.pone.0190849.t001
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as evidenced by the HQ scores and a hyperphagia severity score scale, and were considered in
nutritional phase 3 based on Miller’s classification [2]. Adult patients had a BMI ranging
from 24.2 to 67.4 kg/m2, 23% of them were not obese based on BMI cut-off. BMI was
expressed in Standard Deviation Score for the 3 adolescents with values at 1.1, 0, -0.5. Twenty-
three percent of the adult study population had either IGT or T2D, also in line with published
data [37].
Safety
Overall, 28 patients (59.6%) experienced at least one AE during the study (Table 2). The pro-
portion of patients with AEs was comparable between AZP-531 and placebo treatment groups
(60.9% versus 58.3%, respectively). The most common AEs in both groups were observed at
the injection site with a higher frequency in the placebo group. The majority of AEs was mild
in severity and resolved. The number of events was higher with AZP-531 versus placebo,
mainly due to repeated injection site pain events observed in one single patient. There were no
serious adverse events or AEs leading to treatment discontinuation, and no hypoglycemia
events. There were no significant findings with respect to vital sign parameters and safety labo-
ratory tests.
Food-related behaviors
Globally, mean values of each individual items of the HQ appeared to decrease more with
AZP-531 than with placebo (Fig 2A), resulting in decreases in the calculated scores that were
more pronounced for AZP-531 as compared to placebo (Fig 2B). The severity domain score
decreased in the AZP-531 group only (Fig 2B). This effect was statistically significant versus
placebo (p< .05) for the total score (absolute adjusted mean scores of 24.01 versus 27.56, p =
.0407, treatment effect 95% CI -6.94; -0.16), the 9-item score (17.42 versus 21.03, p = .0146,
95% CI -6.47; -0.75) and the severity domain score (4.06 versus 4.99, p = .0185, 95% CI -1.69;
-0.16). For home-residents, this effect was even larger versus placebo for the total score (abso-
lute adjusted mean scores of 24.02 versus 28.57, p = .0297), the 9-item score (17.43 versus
22.08, p = .0092) and the severity domain score (4.02 versus 5.12, p = .0198). Moreover, sup-
portive non-parametric tests provided similar conclusions. Statistical significance was not
reached for the behavior and drive domain scores in all patients (p = .14 and p = .09, respec-
tively) as well as in home-residents (p = .07 and p = .14, respectively). Improvements in the
total and 9-item scores were significantly larger in AZP-531 treated patients who had higher
scores at baseline (r = -0.5, p = .02 and -0.55, p = .008, respectively). No such significant corre-
lation was found for placebo treated patients (r = -0.04, p = .87 and-0.05, p = .83). As a result,
the between-group difference in the 9-item score change was gradually higher in home resi-
dent patients, in home resident patients with a baseline score19 as compared to all patients
(Fig 3). CDF plots of the change in 9-item HQ score indicate that the percentage of partici-
pants showing improvement was consistently higher in the AZP-351 treatment group than in
the placebo group. This finding was even more pronounced in home-residents and in those
who displayed a HQ score at baseline19 (Fig 4). In addition, no patient in AZP-531 group
had a worsening of the 9-item HQ score while a worsening was observed in the placebo group
(17%, 20% and 25% of all patients, home-residents and home resident patients who have a HQ
score at baseline>19). Comparable CDF plots were observed for the total score.
Appetite feelings
Overall, mean scores of patient-reported feelings of appetite decreased immediately following
meal and returned to baseline 2 hours following meal. At Day 14, values were comparable
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Table 2. Adverse events. Data are expressed in number (and percentage) of patients with adverse events.
Event
number of patients (%)
AZP-531
N = 23
Placebo
N = 24
Any event 14 (60.9) 14 (58.3)
Related event 8 (34.8) 10 (41.7)
Events reported in >5% of the patients
Injection site erythema 1 (4.3) 2 (8.3)
Injection site hematoma 3 (13.0) 6 (25.0)
Injection site pruritus 0 (0) 2 (8.3)
Oropharyngeal pain 0 (0) 2 (8.3)
Somnolencea 2 (8.7) 0 (0)
Events reported in <5% of the patients
Ear pain 1 (4.3) 0 (0)
Vision blurred 1 (4.3) 0 (0)
Abdominal pain 1 (4.3) 0 (0)
Diarrhoea 1 (4.3) 0 (0)
Asthenia 1 (4.3) 0 (0)
Fatigue 0 (0) 1 (4.2)
Feeling cold 1 (4.3) 0 (0)
Hunger 1 (4.3) 0 (0)
Injection site pain 1 (4.3) 0 (0)
Injection site paresthesia 1 (4.3) 0 (0)
Malaise 1 (4.3) 0 (0)
Erysipelas 1 (4.3) 0 (0)
Gastroenteritis 1 (4.3) 0 (0)
Nasopharyngitis 1 (4.3) 0 (0)
Otitis Media 1 (4.3) 0 (0)
Pharyngitis 0 (0) 1 (4.2)
Rhinitis 0 (0) 1 (4.2)
Fall 0 (0) 1 (4.2)
Ligament sprain 1 (4.3) 0 (0)
Scratch 1 (4.3) 0 (0)
Blood TSH decreased 0 (0) 1 (4.2)
Hyperglycaemia 1 (4.3) 0 (0)
PICA 1 (4.3) 0 (0)
Arthralgia 0 (0) 1 (4.2)
Back pain 0 (0) 1 (4.2)
Pain in extremity 0 (0) 1 (4.2)
Torticollis 1 (4.3) 0 (0)
Dizziness 1 (4.3) 0 (0)
Headache 1 (4.3) 0 (0)
Anxiety 1 (4.3) 1 (4.2)
Nightmare 1 (4.3) 0 (0)
Polyuria 1 (4.3) 0 (0)
Ecchymosis 0 (0) 1 (4.2)
Pruritus 1 (4.3) 0 (0)
aPatients who reported somnolence were 23 and 30 years old respectively.
https://doi.org/10.1371/journal.pone.0190849.t002
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between AZP-351 and placebo groups for all time points. Day 14 versus baseline comparisons
revealed a significant decrease in scores for AZP-531 after breakfast (-1.1, p = .0004) while no
significant change versus baseline was noted for placebo (-0.5, p = .10). Values for each treat-
ment group were comparable to baseline at 120 min post-start of breakfast.
Fig 2. Changes in Hyperphagia Questionnaire individual items and calculated scores from baseline to Day 14. Panels A and B show the mean values of each
individual item and each calculated score, respectively. The 9-item score excluded item 3 and item 10 as both items were considered to reflect impression of caregiver
rather than capturing concept of interest. A reduction in the score indicates improvement. Bars indicate the standard error. p< .05 versus placebo.
https://doi.org/10.1371/journal.pone.0190849.g002
Fig 3. Changes in Hyperphagia Questionnaire 9-item score from baseline to Day 14. Panels A, B, and C show the mean change from baseline in the Hyperphagia
Questionnaire 9-item score for all patients (N = 47), home-resident patients (N = 38) and home-resident patients with a threshold base line HQ 9-item score19
(N = 26). A reduction in the score indicates improvement. Bars indicate the standard error.
https://doi.org/10.1371/journal.pone.0190849.g003
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Body composition
Descriptive values for the mean change from baseline to day 14 in study variables are presented
in Table 3. BW did not change significantly at Day 14 in both groups while WC decreased by
-1.14 cm for AZP-531 (p = .047) versus -0.21 cm for placebo (p = .55). Fat mass also decreased
at Day 14 as compared to baseline for both groups, with a change of -1.42% for AZP-531 (p =
.046) and of -0.48% for placebo (p = .52). No significant difference between groups was found
for body composition.
Glycemic measures
There was an overall (Day 1 and Day 14 combined) significant reduction in blood glucose lev-
els versus baseline at 180 minutes post-start of breakfast for AZP-531 vs. placebo (change-
from-baseline adjusted means of -0.21 versus 0.18 mmol/L, p = .008, treatment effect 95%CI
-0.68; -0.11) with p = .05 (95% CI -0.79; 0.00) at Day 1 and p = .04 (95% CI -0.75; -0.02) at Day
14. The reduction appeared greater in AZP-531 patients with IGT or T2D. The decrease in glu-
cose was significantly larger in AZP-531 patients who had higher baseline glucose values (r =
-0.47, p = .03) while such a significant correlation was not seen in placebo (r = -0.17, p = .46)
(Fig 5). In parallel, there was an overall (Day 1 and Day 14 combined) significant effect for a
decrease in insulin levels in AZP-531 versus placebo at 180 min post-start of breakfast
(change-from-baseline adjusted means of -22.31 versus 28.48 pmol/L, p = .02, treatment effect
95% CI -91.77; -9.76) with a trend at Day 1 (p = .05, 95% CI -137.11; 0.93) and no significant
effect at Day 14 (p = .21, 95% CI -86.89; 19.95).
Circulating ghrelin
In both groups, mean AG and UAG values decreased following meal as expected. There were
no relevant changes following treatment in ghrelin values and the ratio.
Fig 4. Cumulative distribution function of the Hyperphagia Questionnaire 9-item score from baseline to Day 14. The percentage of treated participants was
plotted against the change in Hyperphagia Questionnaire 9-item score from baseline to Day 14.
https://doi.org/10.1371/journal.pone.0190849.g004
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Table 3. Changes from baseline to Day 14 in study variables.
Variable AZP-531
N = 23
Placebo
N = 24
n Mean ± SD n Mean ± SD
HQ scores
Total 22 -4.9 ± 5.6a 23 -2.5 ± 6.7
9-item 22 -4.3 ± 5.0a 24 -1.6 ± 5.1
Behavior domain 22 -2.5 ± 3.2 23 -1.4 ± 3.2
Drive domain 23 -1.4 ± 2.4 24 -1.1 ± 2.4
Severity domain 23 -0.9 ± 1.1a 24 0.0 ± 1.6
Appetite scores at breakfast
Fasting 23 0.0 ± 1.3 24 -0.3 ± 1.3
Immediately after 23 -1.1 ± 1.8b 24 -0.5 ± 1.8
2 hours after 23 -0.3 ± 1.5 24 -0.2 ± 1.8
Body composition
Body weight (kg) 23 -0.07 ± 1.61 24 -0.50 ± 2.25
Fat mass (%) 14 -1.42 ± 3.25c 14 -0.48 ± 1.48
WC (cm) 22 -1.14 ± 2.03c 24 -0.21 ± 3.58
Glycemic measures at breakfast
Glucose (mmol/L)
All patients
Fasting 22 -0.06 ± 0.20 24 0.04 ± 0.30
At 60 minutes 22 0.17 ± 1.35 24 0.05 ± 1.16
At 180 minutes 21 -0.23 ± 0.74a 22 0.15 ± 0.41
IGT/T2D patients
Fasting 5 -0.03 ± 0.19 5 0.17 ± 0.27
At 60 minutes 5 -0.53 ± 1.78 5 0.74 ± 0.60
At 180 minutes 5 -0.84 ± 1.14 4 0.00 ± 0.35
Insulin (pmol/L)
All patients
Fasting 21 2.58 ± 35.30 21 3.73 ± 26.69
At 60 minutes 21 2.73 ± 166.03 22 30.14 ± 240.51
At 180 minutes 19 -3.30 ± 78.57 23 30.28 ± 90.33
IGT/T2D patients
Fasting 5 23.39 ± 23.75 4 9.33 ± 34.51
At 60 minutes 5 -74.62 ± 142.64 4 80.58 ±79.50
At 180 minutes 3 -63.86 ± 13.70 5 -8.47 ± 47.50
AG:UAG ratio at breakfast
Fasting 21 0.00 ± 0.20 22 -0.03 ± 0.30
At 60 minutes 19 0.04 ± 0.20 21 -0.01 ± 0.19
At 180 minutes 19 0.05 ± 0.49 20 -0.13 ± 0.45
HQ, hyperphagia questionnaire; IGT, impaired glucose tolerance; T2D: Type 2 diabetes. Data are expressed as mean ± SD.
ap < .05 as compared to placebo (ANCOVA excluding one outlier patient).
bp < .001 as compared to baseline (ANOVA).
cp < .05 as compared to baseline (ANOVA).
https://doi.org/10.1371/journal.pone.0190849.t003
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Discussion
In this study, administration of AZP-531 for 2 weeks to patients with PWS was well tolerated
which corroborates safety data from previous AZP-531 studies in humans where no negative
safety signals were noted following 2 weeks of continuous treatment at doses up to 60 μg/kg/
day in obese subjects and patients with type 2 diabetes [30]. With AZP-531 treatment, there
was a significant improvement in food-related behaviors as reported by caregivers using the
HQ. In the absence of defined clinical endpoints to assess drug efficacy against hyperphagia,
there has been tremendous effort made in the past few years by the academia and the pharma-
ceutical industry to develop and validate clinical outcome measures. The HQ designed by
Dykens at al. has emerged as a reliable and valid tool and a 9-item modified version of the HQ
specifically for use in clinical trials (HQ-CT) has been recently developed incorporating indus-
try guidance related to clinical outcome assessment and FDA recommendations. Based on the
dialogue recently engaged between the industry and regulatory agencies, the 9-item HQ-CT
score has been recently considered as a relevant clinical outcome measurement from a drug
development perspective. In this study, the 9-item score calculated with the same items as the
HQ-CT significantly improved by 2.6 versus placebo after only 2 weeks of treatment. In addi-
tion, post-meal appetite scores were shown to be reduced as compared to baseline with AZP-
531 and not with placebo, suggesting improved satiety following treatment with AZP-531 and
supporting the food-behavior data.
In our study, the improvement for AZP-531 vs placebo in the HQ 9-item score appears
larger in home-resident patients as compared to the whole study population because of lesser
effect especially in foraging and food stealing behaviors in hospital-residents which is not
unexpected in such a supervised and controlled setting. Distribution of the data also indicates
that a significant proportion of patients show scores close to the lowest values, suggesting a
floor effect. This is further demonstrated when a threshold HQ score was applied to the base-
line data (19) which resulted in a treatment effect of 5.2 versus placebo in these methodologi-
cally optimized conditions. This points to the appropriateness of such a methodological
approach for the capture and analyses of HQ data in future development.
Fig 5. Post-prandial glucose change in treated patients from baseline to Day 14. Mean values of the 3-hour post-prandial glucose change from baseline to Day 14
was plotted for all treated patients (Panel A), normoglycemic (NG) patients (Panel B), and patients with Impaired Glucose Tolerance or Type 2 Diabetes (IGT/T2D)
(Panel C).
https://doi.org/10.1371/journal.pone.0190849.g005
AZP-351, an unacylated ghrelin analog, improves hyperphagia in Prader-Willi syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0190849 January 10, 2018 13 / 19
Patients with PWS display aggressive food-seeking behaviors that may result in life-threat-
ening complication such as choking [38] or gastric necrosis and rupture [39]. A 40-year mor-
tality survey recently published shows that these complications are the causes of a significant
proportion of deaths in this patient population [6]. In addition, patients with PWS always have
an increased body fat even when non obese and carry a significant risk of developing cardio-
vascular and metabolic complications that represent one of the leading causes of mortality in
adult patients and contribute to reduced life expectancy [6, 40]. Management of food-related
behaviors and obesity is problematic and represents one of the highest priority medical need
for which there is today no other option than continuous supervision, strict control over access
to food, dietary restriction and regular exercise [41]. Drugs and strategies tested so far includ-
ing available anorexigenic agents, endocannabinoid antagonists, recombinant human Growth
Hormone therapy, and gastric banding or bypass, have been proven ineffective in reducing
hyperphagia or were associated with safety issues [42–44]. There are a few pharmacological
targets that are currently undergoing testing in randomized controlled trials including oxyto-
cin and analogs, GLP-1 analogs, a melanocortin 4 receptor agonist and a K+-ATP agonist. The
clinical development of beloranib, an inhibitor of methionine aminopeptidase 2, has been
recently terminated due to safety issues [45].
Data from the largest cohort ever published on ghrelin in PWS have shown that circulating
AG levels are elevated in patients with PWS when hyperphagia and obesity develop whereas
UAG levels are normal [25], reflecting a relative UAG deficit. This ghrelin pattern appears
unique to PWS suggesting an intrinsic defect in the ghrelin regulation in PWS and is opposed
to common obesity where AG levels (in addition to UAG levels) are decreased versus healthy
controls. The rationale for investigating AZP-531 in patients with PWS was based on experi-
mental evidence indicating that administration of UAG abolished the orexigenic effect of AG
in a rat model [12] and that AZP-531 was able to reproduce this inhibitory effect. Further
investigation showed that UAG suppresses AG-induced hypothalamic neuronal activity
involved in food intake [12] and acts as a functional antagonist of AG. UAG may act indepen-
dently of AG by affecting expression of melanocortin receptors and stimulating nesfatin neu-
rons, pathways also known to modulate food intake [12, 13].
No effect on circulating ghrelin values and the ratio was noted following 14 days of treat-
ment with AZP-531 in this study. This is a consistent finding as no change in ghrelin levels
was observed in previous human studies where healthy subjects, obese subjects and patients
with T2D were treated for up to 14 days with AZP-531 [30]. Plasma AG levels were also
unchanged following UAG treatment to healthy subjects [46] in contrast to a previous report
where decreased AG levels were observed following infusion of UAG to patients with T2D
[47]. This latter finding may be explained by an assay issue.
Here, we also report a significant decrease from baseline in fat mass and waist circumfer-
ence with AZP-531 but not with placebo, with no change in body weight. Furthermore, there
was a significant decrease in post-prandial blood glucose versus placebo that was more pro-
nounced in patients with IGT or T2D, with no change or a decrease in insulin levels. This find-
ing appears of clinical relevance as T2D is reported in about 25% of adults with PWS [37]. The
above-mentioned results were obtained following only 2 weeks of treatment in patients with
heterogeneous body composition data at baseline. Fat mass was assessed by bioelectrical
impedance that has limitations as compared to gold standard dual-energy X-ray absorptiome-
try. Nevertheless, data are consistent with previous findings showing improvement in body
composition, glycemic parameters and insulin sensitivity following treatment with UAG or
AZP-531 in obesity and diabetes conditions in animals and humans and suggest that AZP-531
reproduces these effects on adipose tissue and insulin sensitivity in patients with PWS. In a
high-fat-diet murine model, treatment for 4 weeks with UAG or AZP-531 was shown to
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prevent glucose intolerance, insulin resistance, and fat accumulation, all these effects being
considered as direct peripheral effects of UAG and AZP-531, and were translated into the
clinic [11]. A short-term treatment with UAG improved insulin sensitivity in patients with
Type 2 diabetes [47]. A 2-week treatment with AZP-531 improved glucose concentrations,
without increasing insulin levels, suggesting an insulin sensitizing effect, and decreased body
weight in overweight/obese subjects while patients with Type 2 diabetes had their HbA1c
reduced [30].
Based on these findings, significant improvement in body composition and metabolic
parameters can be reasonably expected in longer-term and larger clinical trials in PWS. This is
also supported by epidemiological reports that link relative UAG deficiencies with higher body
weight and insulin resistance, while correcting body weight is accompanied by an increase in
UAG [48, 49].
In summary, treatment with AZP-531, an UAG analog, for 2 weeks was well-tolerated in
such a frail PWS population and resulted in significant improvement in food-related behaviors
supported by a reduction in hunger, as well as encouraging metabolic signals. Our data war-
rant further investigation to assess long-term safety and efficacy of AZP-531 in patients with
PWS and hyperphagia for whom no approved treatment is currently available.
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